Stoke Therapeutics officer proposes $16.3K share sale

The notice also reports 2,861 shares sold during the prior three months, for an aggregate market value of $91,639.43.

Rhea-AI Filing Summary

Stoke Therapeutics, Inc. officer Jonathan D. Allan reported a proposed sale of 627 common shares, with an approximate sale date of October 2, 2026 and an aggregate market value of $16,308.27. The shares are listed as acquired from the issuer through restricted stock units on September 30, 2026. The notice also lists 2,861 shares sold on August 18, 2026, for $91,639.43 during the prior three months.

Key Figures

Proposed sale: 627 shares Aggregate market value: $16,308.27 Shares sold: 2,861 shares +1 more

4 metrics

Proposed sale 627 shares Common shares listed for sale

Aggregate market value $16,308.27 Proposed sale of 627 shares

Shares sold 2,861 shares August 18, 2026; during the prior three months

Aggregate market value of prior sales $91,639.43 Shares sold during the prior three months

Key Terms

Restricted Stock Units, Rule 144

2 terms

Restricted Stock Units financial

"acquired from the issuer through Restricted Stock Units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Rule 144 regulatory

"the definition of person in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many STOK shares does Jonathan D. Allan plan to sell?

Jonathan D. Allan, an officer of Stoke Therapeutics, reported a proposed sale of 627 common shares, with an approximate sale date of October 2, 2026 and an aggregate market value of $16,308.27.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/02/2026 - 04:21 PM Accepted by SEC EDGAR 10/02/2026 - 04:20 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001966716
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Stoke Therapeutics, Inc.
SEC File Number	001-38938
Address of Issuer	45 Wiggins Ave Bedford MASSACHUSETTS 01730
Phone	7814308200
Name of Person for Whose Account the Securities are To Be Sold	JONATHAN D ALLAN
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	627	16308.27	64526242	10/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/30/2026	Restricted Stock Units	Issuer			627	09/30/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
JONATHAN D ALLAN 45 Wiggins Ave Bedford MA 01730	Common	08/18/2026	2861	91639.43

144: Remarks and Signature

Remarks
Date of Notice	10/02/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/10/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jonathan Allen
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)